within Pharmacolibrary.Drugs.ATC.A;

model A16AX14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.00020833333333333335,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.089,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009333333333333334,
    Tlag           = 20.400000000000002
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AX14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Migalastat is an oral pharmacological chaperone used for the treatment of Fabry disease—a rare X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (GLA). Migalastat stabilizes specific mutant forms of GLA, increasing their trafficking to lysosomes and thus enhancing enzymatic activity. Migalastat is approved for use in several regions including the EU, USA, and Japan.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration of migalastat 150 mg to healthy adult volunteers (mean age approx. 30 years, both sexes) under fasting conditions.</p><h4>References</h4><ol><li><p>Leonowens, C, et al., &amp; Johnson, FK (2022). Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal Impairment. <i>Clinical pharmacology in drug development</i> 11(12) 1367–1381. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1160&quot;>10.1002/cpdd.1160</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36331497/&quot;>https://pubmed.ncbi.nlm.nih.gov/36331497</a></p></li><li><p>McCafferty, EH, &amp; Scott, LJ (2019). Migalastat: A Review in Fabry Disease. <i>Drugs</i> 79(5) 543–554. DOI:<a href=&quot;https://doi.org/10.1007/s40265-019-01090-4&quot;>10.1007/s40265-019-01090-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30875019/&quot;>https://pubmed.ncbi.nlm.nih.gov/30875019</a></p></li><li><p>Johnson, FK, et al., &amp; Boudes, P (2013). Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 2(2) 120–132. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1&quot;>10.1002/cpdd.1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27121667/&quot;>https://pubmed.ncbi.nlm.nih.gov/27121667</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AX14;
